IntrinsicIntrinsic
← All summaries

BrightSpring Health Services, Inc.

BTSGU
Financials & Chart →

Business Summary

BrightSpring Health Services, Inc. operates as a leading home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients, including Senior and Specialty populations such as Behavioral patients. The company's platform addresses critical services for the highest-need and highest-cost patients, with a market of over $2.0 trillion across its business. Americans with five or more chronic conditions make up over 12% of the population and account for 41% of total health care spending, on average spending 14 times more on health services than those without chronic conditions. The company's presence spans all 50 states, and it serves over 465,000 patients daily through approximately 10,500 clinical providers and pharmacists. The industry is characterized by a shift toward value-based care and alternative payment models, with the company positioning itself to benefit from the growing demand for home and community-based care.

The company operates in a highly competitive U.S. healthcare industry, competing with a broad and diverse set of businesses spanning both pharmacy and provider services. In the Pharmacy Solutions segment, competitors include Option Care Health, Inc., Coram CVS/specialty infusion services (a division of CVS Health), Accredo Health Group, Inc. (a unit of Cigna), Optum Specialty Pharmacy (a subsidiary of OptumRx, which is a unit of the UnitedHealth Group), and Omnicare, Inc., a division of CVS Health. In the Provider Services segment, the company competes with local, regional, and national providers of home health, hospice, rehab therapy, personal, primary care, and behavioral health services. The company's stated competitive advantages include its integrated and scaled model, market-leading scale as one of the largest independent platforms of both pharmacy and provider services, a focus on operational excellence, and a differentiated approach to care delivery for complex patients. The company's scale provides complementary diversification and risk mitigation in payor sources, end markets, and geographies, while also creating exposure to a broader set of market growth opportunities.

The company generates revenue through two reportable segments: Pharmacy Solutions and Provider Services. Revenue is primarily derived from federal, state, and local government programs such as Medicare (including Parts A, B, C, and D) and Medicaid, as well as from commercial insurance, pharmacy benefit managers (PBMs), and private pay consumers. The company's pharmacy services are reimbursed directly by some skilled nursing and rehabilitation facilities, hospice providers, hospitals, and other provider customers. The business model is characterized by recurring revenue streams, as almost all clients and patients served have chronic conditions and the vast majority receive services on a recurring basis over long periods of time. The company's integrated model is designed to provide complementary pharmacy and provider services to address multiple patient needs, with many patients receiving both pharmacy and provider services from the company.

The Pharmacy Solutions segment provides pharmacy services when and where demanded to customers and patients in their homes and communities. The company filled over 43 million prescriptions in 2025 from over 175 pharmacies across all 50 states, with services delivered to approximately 6,600 customer locations, approximately 73,000 individual or group homes, and over 410,000 patients, all through over 4,500 unique customer and payor contracts. This segment is further divided into Infusion and Specialty Pharmacy and Home and Community Pharmacy. Infusion and Specialty Pharmacy provides infused, injectable, and oral medication services in the home and clinic, focusing on pharmaceutical therapies that require expert administration and high-touch clinical services. The company currently has 149 limited distribution oncology drugs in the market with an additional 18 still to launch, including 4 exclusive and 16 ultra-narrow drugs with limited pharmacy access. Home and Community Pharmacy ensures medications are accessible and clinically supported for patients outside of retail pharmacies, with a localized model that features 'white-glove' and customized programs. The company's pharmacy services achieve 99.99% order accuracy and 99.34% order completeness. For the year ended December 31, 2025, Pharmacy Solutions segment revenue was $11,445.8 million , representing 88.7% of total revenue.

The Provider Services segment delivers clinical and supportive care to high-need, chronic, and complex patients in home and community settings. Following the Community Living divestiture, these services consist of clinical and supportive care to approximately 16,000 Senior and Specialty populations. This segment includes Home Health Care, Rehab Care, and Personal Care services. Home Health Care provides patient-centric clinical care to Seniors and others in their homes, including hospice services, and has a 9.4 HCI score. Rehab Care provides highly-skilled patient-centric clinical care to Senior and Specialty clients and patients, including physical, speech and occupational therapy and ABA therapies. Personal Care provides home care support that assists with activities of daily living. The company's home-based primary care has delivered a hospital readmission rate 35% less than the national average. For the year ended December 31, 2025, Provider Services segment revenue was $1,464.8 million , representing 11.3% of total revenue.

On January 17, 2025, the company entered into a purchase agreement with National Mentor Holding, Inc. to divest the Community Living business for $835 million , subject to typical adjustments for working capital and other customary items, with the transaction expected to close in the first fiscal quarter of 2026. During the year ended December 31, 2025, the company completed three acquisitions within the Provider Services segment for aggregate consideration, net of cash acquired, of approximately $247.0 million . The company also completed two underwritten secondary offerings of its common stock by affiliates of Kohlberg Kravis Roberts & Co. L.P. and certain members of management in June 2025 and October 2025. In connection with the October 2025 secondary offering, the company repurchased 1,500,000 shares of common stock. On February 21, 2024, the company used a portion of the net proceeds from the IPO and the concurrent public offering of the 6.75% Tangible Equity Units to repay $343.3 million of the borrowings under the First Lien Term Loan Facility and to repay all borrowings under the Second Lien Facility.

For the fiscal year ended December 31, 2025, total revenue grew by $2.8 billion, or 28.2%, to $12.9 billion , compared to $10.1 billion in the prior year. Net income increased by $173.7 million from a net loss of $68.9 million to net income of $104.8 million . Diluted income per share increased by $0.82 from diluted loss per share of $(0.34) to diluted income per share of $0.48 . Adjusted EBITDA increased by $157.4 million, or 34.2%, to $617.6 million from $460.2 million in the prior year. Adjusted EPS increased by $0.65 from $0.35 to $1.00 .

Business Outlook

A primary growth vector is the continued expansion of the Pharmacy Solutions segment, particularly in Infusion and Specialty Pharmacy. The company highlights that Infusion and Specialty Pharmacy prescriptions have grown at more than 27% from December 2024 to December 2025. The company sees meaningful new opportunities, such as $90 billion expected by 2032 in pharmaceutical industry revenue from oncology drugs not yet launched, drugs that will become generic over the next five years, and over 415 drug therapies in Phase III in the Infusion and Specialty Pharmacy pipeline. The company also has 149 limited distribution oncology drugs in the market with an additional 18 still to launch, including 4 exclusive and 16 ultra-narrow drugs with limited pharmacy access. The company expects to continue to increase its share in its respective pharmacy patient markets, with growth in serving numerous patient types well into the double digits, including home infusion patients, specialty oncology patients, behavioral patients, in-home Seniors, and hospice patients.

Another key growth vector is the Provider Services segment, with a focus on home health, rehab, primary care, and hospice services following the planned divestiture of the Community Living business. The company states that both census for Home Health Care services and rehab hours served have grown approximately 9% and 12% from December 2024 to December 2025, respectively. The company believes the divestiture will augment the company's expected Revenue and Adjusted EBITDA growth rates and maximize exposure to target growth markets. The company also sees significant potential for additional integrated care opportunities by leveraging its Home-Based Primary Care, CCRx, and Clinical (Nursing) Hub capabilities to support senior living communities, payors, hospital partners, and skilled nursing and rehabilitation facility customers. The company has entered into several ACO arrangements to participate in shared savings from its attributed primary care patients and other ACO partnerships.

The company's margin trajectory is supported by operational excellence initiatives and cost management. The company's PMO-led continuous improvement program has resulted in approximately $84.7 million of annual savings in 2025 from improved processes. The company has also demonstrated economies of scale, with selling, general, and administrative expenses growing less than the volume growth rate in both segments. The company's gross profit margin for the Pharmacy Solutions segment was 8.2% for the year ended December 31, 2025, compared to 8.5% for the prior year, with the decrease attributed to mix shift. The company continues to focus on cost initiatives including formulary product focus, delivery route optimization, and vehicle and mileage optimization.

The company's operational outlook includes continued investments in technology and information systems to support its businesses, including new and improved EMR and ERP systems, a cloud-based data lake and business intelligence capabilities, and continued exploration of automated technologies. The company has approximately 500 human resources professionals supporting its businesses and enterprise functions. The company has had approximately 70% retention of clinical positions in home health care, hospice care, and rehab care from December 31, 2024 to December 31, 2025. The company has consistently increased investments in compensation and benefits, with compensation up over 50% in the last four years. As of December 31, 2025, the company had over 23,500 full-time equivalent employees, with approximately 3,500 full-time equivalent employees represented by labor unions.

The company's capital allocation strategy includes investing in organic growth through de novo locations, with 7 de novo offices opened in 2025 and 150 de novo offices opened since January 1, 2018. The company also pursues acquisitions, completing three acquisitions in 2025 for aggregate consideration of approximately $247.0 million . The company's capital expenditure plans are not explicitly quantified in the filing, but the company notes it has continued to invest greater amounts into technology resources and systems. The company has no current plans to pay cash dividends on its common stock. As of December 31, 2025, the company had $475.0 million of borrowing capacity available under the Revolver. The company repurchased 1,500,000 shares of common stock in connection with the October 2025 secondary offering, and as of December 31, 2025, the entire capacity available under that stock repurchase program had been utilized.

A significant headwind is the company's substantial indebtedness, with approximately $2,521.3 million outstanding under the First Lien Term Loan Facility as of December 31, 2025. The company's high level of indebtedness requires it to dedicate a substantial portion of its cash flows to debt service payments and reduces funds available for other purposes. The company is also subject to interest rate risk, as $1.1 billion of its outstanding debt remained subject to variable rates of interest as of December 31, 2025, while $1.5 billion notional amount was fixed through interest rate swap agreements. Changes to Medicare and Medicaid rates or methods governing payments for services could materially adversely affect the business, as the company derives substantial revenue from these government healthcare programs. The company also faces risks related to the transition of Medicaid and Medicare beneficiaries to managed care organizations, which may limit market share and could adversely affect revenues.

The company faces structural headwinds from the highly competitive nature of the U.S. healthcare industry, with competition from local, regional, and national providers in both pharmacy and provider services. The company's business is reliant on federal and state spending and budget decisions, which may fluctuate under different political conditions. The company also faces risks related to changes in drug utilization and pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement that may negatively impact profitability. The company's growth strategy is partially dependent upon its ability to identify and successfully complete acquisitions, and any failure to manage or integrate acquisitions successfully may have a material adverse effect. The company also faces risks related to the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel.

Risk Factors

The company operates in a highly competitive industry, competing with national, regional, and local providers in both pharmacy and provider services, including Option Care Health, Inc., Coram CVS/specialty infusion services, Accredo Health Group, Inc., Optum Specialty Pharmacy, and Omnicare, Inc. The company's substantial indebtedness of approximately $2.6 billion as of December 31, 2025, with $2,521.3 million outstanding under the First Lien Term Loan Facility, requires a substantial portion of cash flows to be dedicated to debt service payments and limits the company's ability to obtain additional financing, make capital expenditures, or react to competitive pressures. Changes to Medicare and Medicaid rates or methods governing payments could materially adversely affect the business, as the company derives substantial revenue from these government programs, with Medicare Part D representing 31.7% of total revenue and Medicare Part C representing 18.7% of total revenue for the year ended December 31, 2025. The company's business is reliant on federal and state spending and budget decisions, and any reduction in government expenditures or failure to complete the federal budget process could result in payment delays or reductions. The company faces risks related to changes in drug utilization and pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, with the Inflation Reduction Act of 2022 including provisions that may impact the business, such as reducing the out-of-pocket spending cap for Medicare Part D beneficiaries to $2,000 starting in 2025 and allowing the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs.

Management Priorities

Management's message emphasizes the company's position as a leading home and community-based healthcare services platform with a differentiated approach to care delivery. Key themes include the company's focus on delivering complementary pharmacy and provider services to complex patients, its market-leading scale, and its operational excellence. Management highlights the company's quality outcomes, including 99.99% order accuracy and 99.34% order completeness across its pharmacies, 100% patient satisfaction in outpatient rehab services, an 87% overall rating of care in hospice, and hospitalizations that are 35% lower than the national average in home-based primary care. The strategic priorities emphasized for the period ahead include the successful divestiture of the Community Living business to streamline service offerings and focus on senior and specialty populations, continued growth in the Pharmacy Solutions segment particularly in Infusion and Specialty Pharmacy, and the expansion of integrated and value-based care capabilities through Home-Based Primary Care, CCRx, and the Clinical (Nursing) Hub. Management also emphasizes the company's culture and LEGACY focus, which guides every member of the team to act professionally and responsibly.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Segment Results of Operations
  2. [2] Item 7, MD&A — Segment Results of Operations
  3. [3] Item 1, Business — Discontinued Operations
  4. [4] Item 7, MD&A — Factors Affecting Results of Operations and Comparability
  5. [5] Item 5, Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  6. [6] Item 7, MD&A — Liquidity and Capital Resources
  7. [7] Item 7, MD&A — Consolidated Results of Operations
  8. [8] Item 7, MD&A — Consolidated Results of Operations
  9. [9] Item 7, MD&A — Consolidated Results of Operations
  10. [10] Item 7, MD&A — Consolidated Results of Operations
  11. [11] Item 7, MD&A — Non-GAAP Financial Measures
  12. [12] Item 7, MD&A — Non-GAAP Financial Measures
  13. [13] Item 7, MD&A — Non-GAAP Financial Measures
  14. [14] Item 7, MD&A — Non-GAAP Financial Measures
  15. [15] Item 7, MD&A — Non-GAAP Financial Measures
  16. [16] Item 7, MD&A — Non-GAAP Financial Measures
  17. [17] Item 1, Business — Operational Excellence
  18. [18] Item 7, MD&A — Factors Affecting Results of Operations and Comparability
  19. [19] Item 7, MD&A — Liquidity and Capital Resources
  20. [20] Item 5, Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  21. [21] Item 7, MD&A — Liquidity and Capital Resources
  22. [22] Item 1A, Risk Factors — Risks Related to Our Indebtedness
  23. [23] Item 7, MD&A — Liquidity and Capital Resources
  24. [24] Item 7, MD&A — Payor Mix
  25. [25] Item 7, MD&A — Payor Mix
  26. [26] Item 7, MD&A — Consolidated Results of Operations
  27. [27] Item 7, MD&A — Consolidated Results of Operations
  28. [28] Item 7, MD&A — Consolidated Results of Operations
  29. [29] Item 7, MD&A — Consolidated Results of Operations
  30. [30] Item 7, MD&A — Non-GAAP Financial Measures
  31. [31] Item 7, MD&A — Non-GAAP Financial Measures
  32. [32] Item 7, MD&A — Consolidated Results of Operations
  33. [33] Item 7, MD&A — Consolidated Results of Operations
  34. [34] Item 7, MD&A — Consolidated Results of Operations
  35. [35] Item 7, MD&A — Consolidated Results of Operations
  36. [36] Item 7, MD&A — Non-GAAP Financial Measures
  37. [37] Item 7, MD&A — Non-GAAP Financial Measures
  38. [38] Item 7, MD&A — Consolidated Results of Operations
  39. [39] Item 7, MD&A — Consolidated Results of Operations
  40. [40] Item 7, MD&A — Consolidated Results of Operations
  41. [41] Item 7, MD&A — Consolidated Results of Operations
  42. [42] Item 7, MD&A — Consolidated Results of Operations
  43. [43] Item 7, MD&A — Segment Results of Operations
  44. [44] Item 7, MD&A — Segment Results of Operations
  45. [45] Item 7, MD&A — Segment Results of Operations
  46. [46] Item 7, MD&A — Segment Results of Operations
  47. [47] Item 7, MD&A — Liquidity and Capital Resources
  48. [48] Item 7, MD&A — Liquidity and Capital Resources

Analysis on 6/9/2026